KalVista Pharmaceuticals (KALV) to Release Quarterly Earnings on Tuesday

KalVista Pharmaceuticals (NASDAQ:KALV) is anticipated to release its Q4 2026 results after the market closes on Tuesday, March 24th. Analysts expect KalVista Pharmaceuticals to post earnings of ($0.5263) per share and revenue of $32.2860 million for the quarter. Parties may visit the the company’s upcoming Q4 2026 earning results page for the latest details on the call scheduled for Friday, March 27, 2026 at 1:00 AM ET.

KalVista Pharmaceuticals Price Performance

Shares of KALV opened at $17.00 on Friday. The stock’s 50-day moving average price is $15.80 and its two-hundred day moving average price is $14.37. KalVista Pharmaceuticals has a 1 year low of $9.23 and a 1 year high of $19.00. The stock has a market cap of $859.35 million, a P/E ratio of -4.30 and a beta of -0.35. The company has a current ratio of 7.22, a quick ratio of 7.21 and a debt-to-equity ratio of 8.18.

Analysts Set New Price Targets

KALV has been the subject of several recent research reports. Wall Street Zen upgraded KalVista Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, December 6th. Needham & Company LLC lifted their price objective on KalVista Pharmaceuticals from $28.00 to $32.00 and gave the company a “buy” rating in a report on Tuesday, January 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research report on Thursday, January 22nd. HC Wainwright increased their target price on KalVista Pharmaceuticals from $27.00 to $37.00 and gave the stock a “buy” rating in a report on Friday, January 9th. Finally, TD Cowen restated a “buy” rating on shares of KalVista Pharmaceuticals in a research report on Wednesday, December 3rd. Seven equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $29.40.

Insider Activity

In other news, CEO Benjamin L. Palleiko sold 10,034 shares of KalVista Pharmaceuticals stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $15.57, for a total value of $156,229.38. Following the transaction, the chief executive officer owned 442,883 shares in the company, valued at approximately $6,895,688.31. This trade represents a 2.22% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Brian Piekos sold 1,767 shares of KalVista Pharmaceuticals stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $15.57, for a total value of $27,512.19. Following the completion of the transaction, the chief financial officer owned 13,762 shares in the company, valued at approximately $214,274.34. The trade was a 11.38% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 33,378 shares of company stock valued at $522,290 in the last three months. Company insiders own 4.30% of the company’s stock.

Institutional Trading of KalVista Pharmaceuticals

Several large investors have recently bought and sold shares of KALV. BNP Paribas Financial Markets raised its stake in KalVista Pharmaceuticals by 47.0% during the second quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock worth $46,000 after acquiring an additional 1,292 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of KalVista Pharmaceuticals in the third quarter worth about $55,000. Truvestments Capital LLC boosted its stake in shares of KalVista Pharmaceuticals by 253.8% in the 4th quarter. Truvestments Capital LLC now owns 4,684 shares of the specialty pharmaceutical company’s stock valued at $76,000 after purchasing an additional 3,360 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of KalVista Pharmaceuticals by 816.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 8,059 shares of the specialty pharmaceutical company’s stock valued at $91,000 after purchasing an additional 7,180 shares during the last quarter. Finally, Sei Investments Co. bought a new stake in shares of KalVista Pharmaceuticals during the 3rd quarter valued at approximately $145,000.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.